Item 8.01. Other Events.

On October 25, 2022, UnitedHealth Group Incorporated (the "Company") agreed to sell its (i) 5.000% Notes due October 15, 2024 in the aggregate principal amount of $500,000,000, (ii) 5.150% Notes due October 15, 2025 in the aggregate principal amount of $750,000,000, (iii) 5.250% Notes due February 15, 2028 in the aggregate principal amount of $1,000,000,000, (iv) 5.300% Notes due February 15, 2030 in the aggregate principal amount of $1,250,000,000, (v) 5.350% Notes due February 15, 2033 in the aggregate principal amount of $2,000,000,000, (vi) 5.875% Notes due February 15, 2053 in the aggregate principal amount of $2,000,000,000 and (vii) 6.050% Notes due February 15, 2063 in the aggregate principal amount of $1,500,000,000 (collectively, the "Notes"), pursuant to the Underwriting Agreement, dated October 25, 2022 (the "Underwriting Agreement"), and the Pricing Agreement, dated October 25, 2022 (the "Pricing Agreement"), both among the Company and BofA Securities, Inc., Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters listed in Schedule I to the Pricing Agreement.

The Notes were issued on October 28, 2022 pursuant to the Indenture, dated as of February 4, 2008, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Indenture"), and the Officers' Certificates and Company Orders, each dated October 28, 2022, relating to each series of the Notes, in each case, pursuant to Sections 201, 301 and 303 of the Indenture.

The Notes have been registered under the Securities Act of 1933, as amended, pursuant to the Company's automatic shelf registration statement on Form S-3, File No. 333-236600 (the "Registration Statement"). The Company is filing this Current Report on Form 8-K to file with the Securities and Exchange Commission certain documents related to the issuance of the Notes that will be incorporated by reference into the Registration Statement as exhibits thereto.

The Underwriting Agreement is filed herewith as Exhibit 1.1. The Pricing Agreement is filed herewith as Exhibit 1.2. The Officers' Certificates and Company Orders relating to the Notes, each including the applicable form of Note, are filed herewith as Exhibit 4.1, Exhibit 4.2, Exhibit 4.3, Exhibit 4.4, Exhibit 4.5, Exhibit 4.6 and Exhibit 4.7. The legal opinion with respect to the validity of the Notes is filed herewith as Exhibit 5.1.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

Exhibit                                  Description

 1.1         Underwriting Agreement, dated October 25, 2022, among the Company and
           BofA Securities, Inc., Barclays Capital Inc., Citigroup Global Markets
           Inc., J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc. and
           Wells Fargo Securities, LLC, as Representatives of the several
           Underwriters

--------------------------------------------------------------------------------


 1.2       Pricing Agreement, dated October 25, 2022, among the Company and BofA
         Securities, Inc., Barclays Capital Inc., Citigroup Global Markets Inc.,
         J.P. Morgan Securities LLC, U.S. Bancorp Investments, Inc. and Wells
         Fargo Securities, LLC, as Representatives of the several Underwriters

 4.1       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.000% Notes due October 15, 2024, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.000%
         Notes due October 15, 2024)

 4.2       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.150% Notes due October 15, 2025, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.150%
         Notes due October 15, 2025)

 4.3       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.250% Notes due February 15, 2028, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.250%
         Notes due February 15, 2028)

 4.4       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.300% Notes due February 15, 2030, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.300%
         Notes due February 15, 2030)

 4.5       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.350% Notes due February 15, 2033, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.350%
         Notes due February 15, 2033)

 4.6       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 5.875% Notes due February 15, 2053, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 5.875%
         Notes due February 15, 2053)

 4.7       Officers' Certificate and Company Order, dated October 28, 2022,
         relating to the 6.050% Notes due February 15, 2063, pursuant to
         Sections 201, 301 and 303 of the Indenture (including the form of 6.050%
         Notes due February 15, 2063)

 5.1       Opinion of Hogan Lovells US LLP regarding the validity of the Notes

23.1       Consent of Hogan Lovells US LLP (included as part of Exhibit 5.1)

104      Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses